EFGCP Conference 2026
Uniting for Success: A Multi-stakeholder Vision for Ethical Review in Europe
Europe is at a defining moment for clinical research. The Clinical Trials Regulation set out a powerful vision: a continent united by transparency, collaboration, and efficient access to innovation. While its implementation brought both progress and pressure, it confirmed something essential—Europe’s commitment to ethics, quality, and patient protection remains unwavering.
National ethical review is a vital strength of Europe’s clinical research landscape. Ethics committees play a key role in ensuring trials uphold human dignity, scientific integrity, and public trust. Their contribution, together with the regulatory authorities' risk-benefit review, forms the foundation of a credible and high‑quality research ecosystem. By further strengthening the collaborative partnership, Europe can achieve an ethical review process that is both protective and efficiently aligned with the needs of modern clinical research.
Today, national ethical review stands at the centre of the conference discussion. Ethics committees face growing complexity; sponsors navigate longer reviews and more information requests. These challenges highlight not failure, but opportunity: the chance to rethink how Europe aligns ethical excellence with operational efficiency.
In addition, the European Commission’s proposed new Biotech Act offers a fresh pathway—clearer roles, streamlined processes, and modern ethical standards grounded in the 2024 Declaration of Helsinki. It invites us to shape a system worthy of Europe’s innovation leadership ambitions.
The EFGCP Conference 2026 is where this work begins. Here, stakeholders from across Europe come together to share best practice experiences, challenge assumptions, and co‑create practical solutions to optimise the system. Our goal is simple and ambitious: to strengthen participant protection while enabling efficient, faster, more predictable clinical trial authorisations and start up times.
Together, we have the opportunity to build an ethical review model that reflects Europe at its best—responsible, collaborative, transparent and ready to lead the next chapter of global research.
NEW:
Registering to this event now grant free participation to the complementary Virtual Pre-Conference Workshop, select "Combined Events" after clicking on "Register Here" on this page to benefit from this offer.
Join us early on site on the 12th of May to get the opportunity to Network with colleagues around a coffee, and enjoy a Lunch* before the Main Conference starts!
A Networking Dinner* is also planned on the 12th of May evening, after the closure of the day.
*Registrants will be contacted after settling their registration on the website to confirm their participation to networking events and provide their diet requirements.
Programme
| 09:30 |
Welcome Desk and Registrations Opening |
| 09:30 |
Welcome coffee, networking, and discussions in the lobby |
| 12:00 |
Networking Lunch |
| 13:00 |
Welcome and Introduction to the EFGCP Conference 2026
Angelika Joos, MSD
Ingrid Klingmann, Pharmaplex, EFGCP
Jozef Glaza, Slovak Medical University in Bratislava, EFGCP
|
| 13:15 |
Session 1: The current situation of clinical trials and their ethical review in 4 years under the CTR Moderator(s): Angelika Joos, MSD Mary-Lynne Van Poelgeest-Pomfret, World Federation of Incontinent Patients, EFGCP |
|
Clinical Trials – Current conditions impacting EU attractiveness between perceptions and reality
Christopher Bamford, IQVIA
|
|
|
Industry perspective on EU competitiveness
Manan Trivedi, UCB
|
|
|
European Commission proposal for the BioTech Act to foster European competitiveness in clinical research
Corinna Hartung, European Commission, DG Santé
|
|
| 14:30 |
Coffee Break |
| 14:45 |
Break-out Sessions on experiences with national Ethics Committee Systems |
|
Break-out Group 1 – Decentralised Model (F2F Attendance Only) Moderator(s): Christopher Bamford, IQVIA Ingrid Klingmann, Pharmaplex, EFGCP |
|
|
Belgium Jelle Klein, SGS Belgium NV Katelijne Anciaux, Clinical Trial College |
|
|
France Jean-Marc Davy, Commission nationale des recherches impliquant la personne humaine (CNRIPH) Seif Eddine Amara Madi, GSK |
|
|
Germany Robert Schultz-Heienbroek, Charité Research Organisation |
|
|
Italy Cinzia Dorigo, Alexion Roberto Poscia, National Coordination Center for Regional Ethics Committees |
|
|
Spain Elena Garcia Mendez, Ethics Committee of Hospital Universitario La Paz Maria Sanchez, MSD |
|
|
The Netherlands Amos de Jong, University Medical Centre Utrecht Michel Zwaan, Princes Maxima Centrum |
|
|
Break-out Group 2 – Centralized Model (F2F Attendance Only) Moderator(s): Birka Lehmann, University Bonn Jozef Glaza, Slovak Medical University in Bratislava, EFGCP |
|
|
Estonia Janek Kapper, Estonian Inflammatory Bowel Disease Association |
|
|
Denmark Kaja Borup Løvschall, Danish Health Authority, National Center for Ethics |
|
|
Finland Marko Ahteensuu, Tukija, Finnish Ethics Committee Supervisory Agency |
|
|
Greece Varvara Baroutsou, IFAPP |
|
|
Poland Aneta Sitarska Haber, Polish Association for Good Clinical Practice Monika Trawinska, Medical Research Agency |
|
|
Portugal Rafael Vale e Reis, University of Coimbra Sonia Carvalho, AICIB |
|
|
Slovakia Helena Glasová, Slovak Medical University |
|
|
Virtual Break-out Group Open 3 – Global experience: What experience tells us about successful elements of clinical review in different countries: Trust or Trustworthiness?
(Online Attendance Only) Moderator(s): Heather Sampson, University of Toronto, EFGCP Hugh Davies, Oxford A Research Ethics Committee |
|
| 17:00 |
Jozef Hoet Award Ceremony
Ingrid Klingmann, Pharmaplex, EFGCP
|
| 18:00 |
Close of the Day and Networking Dinner |
| 08:30 |
Welcome Coffee |
| 09:00 |
Session 2: What can we learn from each other? Moderator(s): Helle Christiansen, Danish National Center for Ethics Solange Corriol-Rohou, Consultant, EFGCP |
| 10:45 |
Coffee Break |
|
Session 3: How can we increase Europe’s competitiveness while ensuring leading ethical review standards and optimal participant protection? Moderator(s): Blanca Garcia-Ochoa, MSD Joop van Gerven, Chair MERB Amsterdam UMC |
|
| 11:15 |
MedEthicsEU: Current and planned future approach to harmonisation and facilitation of ethical review
Monique Al, CCMO, MedEthics EU
|
| 11:45 |
Open Forum Discussion |
|
Introduction: European Commission Proposal for Revising the Clinical Trials Regulation with a Focus on the Ethical Review Corinna Hartung, European Commission DG Santé
Corinna Hartung, European Commission, DG Santé
|
|
|
Discussion: What needs to be done to ensure reliable, efficient ethical review in the coordinated assessment procedure? Will Fast-EU provide the pilot testbed?
Cinzia Dorigo, Alexion
Corinna Hartung, European Commission, DG Santé
Dominique Sprumont, EUREC, CIOMS, Ethics committee of Vaud
Manan Trivedi, UCB
Monique Al, CCMO, MedEthics EU
|
|
| 13:00 |
Panel and Open Forum Discussion and Slido collection of opinions from the audience onsite and online: Recommendations for the future ethical review of clinical trials from the EFGCP Conference 2026 multi-stakeholder participants
Angelika Joos, MSD
Ingrid Klingmann, Pharmaplex, EFGCP
Jozef Glaza, Slovak Medical University in Bratislava, EFGCP
|
| 13:45 |
Conclusions and next steps |
